Will the level of leucodepletion prevent my patient becoming alloimmunised and/or refractory to platelet transfusions?
The reduction in HLA alloimmunisation as a result of leucodepletion of blood components, especially for multiply transfused patients and transplant recipients, is well established. The level of leucodepletion used by ARCBS is comparable to that achieved in the studies that have shown this benefit.
Related Questions
- Patient Visits: Is the Committee interested in whether residents achieve a specific number of patient visits per PGY level?
- Will the level of leucodepletion prevent my patient becoming alloimmunised and/or refractory to platelet transfusions?
- Will the level of leucodepletion prevent my patient getting febrile non-haemolytic (FNH) reactions?
